Cargando…
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
Introduction: Fifty years after the discovery of Δ(9)-tetrahydrocannabinol (THC) as the psychoactive component of Cannabis, we are assessing the possibility of translating this herb into clinical treatment of inflammatory bowel diseases (IBDs). Here, a discussion on the problems associated with a po...
Autores principales: | Hasenoehrl, Carina, Storr, Martin, Schicho, Rudolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388177/ https://www.ncbi.nlm.nih.gov/pubmed/28276820 http://dx.doi.org/10.1080/17474124.2017.1292851 |
Ejemplares similares
-
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
por: Liu, Eleanor, et al.
Publicado: (2022) -
Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020) -
Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017) -
Neuropsychiatry: Where Are We And Where Do We Go From Here?
por: Sachdev, Perminder S., et al.
Publicado: (2013) -
Artificial intelligence and inflammatory bowel disease: Where are we going?
por: Da Rio, Leonardo, et al.
Publicado: (2023)